

## Information about proposed Board of Directors Annual General Meeting 2025

---

### *Proposal for re-election of the current members of the Board of Directors:*

#### **Christophe Bourdon**

Born 1970. Master of Business Administration from International Institute for Management (IMD) Business School, Switzerland, and a BA from ISG Business School, France. Board member since 2023.

*Other appointments:* CEO of Leo Pharma A/S.

*Previous appointments:* CEO of Orphazyme A/S, Senior Vice President, General Manager, U.S Oncology Business and member of the Operating Team at Amgen Inc., Senior Vice President of Europe, Middle East, Africa and Canada at Alexion, as well as other key roles within the international pharmaceutical industry.

*Shares:* 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.

#### **David Meek**

Born 1963. Bachelor of Arts (Management) from the University of Cincinnati, USA. Board member since 2024.

*Other appointments:* Board member of Cullinan Therapeutics, uniQure (Chair) and the University of Southern California School of Pharmacy and Pharmaceutical Sciences.

*Previous appointments:* Chief Executive Officer and Board Director of Mirati Therapeutics Inc FerGene Inc and Ipsen SA. Senior executive positions at Baxalta Inc, Endocyte Inc, Novartis Pharmaceuticals and Johnson & Johnson

*Shares:* 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.

#### **Zlatko Rihter**

Born 1970. Master of Science in Mechanical Engineering from Lund University, Sweden. Board member since 2024.

*Other appointments:* CEO of Mölnlycke Health Care AB.

*Previous appointments:* President and CEO at CellaVision, Executive Vice President Sales & Marketing at ORIGIO, President GBU Chronic at Gambro and Director Patient Handling Product Division at ArjoHuntleigh. Board member of Malmö FF and Etac Group.

*Shares:* 10,000

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.

**Helena Saxon**

Born 1970. Master of Science from Stockholm School of Economics, Sweden. Board member since 2011.

*Other appointments:* Board member of H&M, SEB and Stockholm School of Economics.

*Previous appointments:* CFO and Vice President at Investor AB, CFO at Hallvarsson & Halvarsson, and financial analyst at Goldman Sachs. Board member of Aleris and Mölnlycke Health Care.

*Shares:* 22,856

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.

**Staffan Schüberg**

Born 1969. Bachelor of Arts (Hons) Business Administration from the London Guildhall University, United Kingdom. Board member since 2020.

*Other appointments:* CEO of the ESTEVE Group. Board member of Dizlin Pharmaceuticals AB and Corporación Químico Farmacéutico Esteve S.A.

*Previous appointments:* More than 20 years of experience from Board and executive management roles, including several senior positions within Lundbeck A/S, such as Regional Vice President for Southern and Western Europe, President and Chairman of the U.S. operations and Global Chief Commercial Officer on Group level.

*Shares:* 7,142

Independent in relation to the company and its management and in relation to the company's principal shareholders.

**Filippa Stenberg**

Born 1985. Master of Science in economics from Stockholm School of Economics, Sweden. Board member since 2021.

*Other appointments:* Managing Director at Investor AB.

*Previous appointments:* Chief Strategy Officer at Atlas Antibodies. Analyst at Swedbank LC&I.

*Shares:* 571

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.

**Anders Ullman**

Born 1956. MD, PhD in Clinical Pharmacology from the University of Gothenburg, Sweden. Board member since 2023.

*Other appointments:* Board member of Verona Pharma plc.

*Previous appointments:* Head of Research & Development and Medical Affairs and Chief Medical Officer at Sobi. Head of the COPD Centre at Sahlgrenska University Hospital. Board member of Sobi, NeuroSearch and PExA. More than 20 years of experience from several executive positions within research and development in the international pharmaceutical industry, including Baxter Bioscience, Nycomed/Takeda, Biovitrum, Bayer Pharmaceuticals and AstraZeneca.

*Shares:* 3,429

Dependent in relation to the company and its management but independent in relation to the company's principal shareholders.

***Proposal for election of a new member of the Board of Directors:***

Iris Loew-Friedrich

Born 1960. MD, PhD in internal medicine from Goethe University Frankfurt, Germany.

*Other appointments:* Chair of the Board of Evotec SE and of Celosia Therapeutics Pty Ltd. Board member of Fresenius SE & Co. KGaA. Member of the advisory boards of Spave Science Inc., Fondazione Telethon, Pierre Fabre S.A. and Helmholtz Health.

*Previous appointments:* Executive Vice President, Chief Medical Officer and Head of Development at UCB S.A/Schwarz Pharma AG, Vice President, Head of Global Development at BASF Pharma and various positions in clinical development at Aventis/Hoechst Marion Roussel/Hoechst AG (changed names due to mergers).

*Shares:* 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.